Novo Nordisk’s Saxenda Initially Positioned For Private Patients In Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
Obese patients who are severely ill with a high BMI and co-morbidities, and who are highly motivated to try a new therapy and willing to pay for it out-of-pocket, will be targeted for Saxenda.